Coya Therapeutics Expands Sponsored Research Collaboration With Houston Methodist Research Institute With Funding From Johnson Center For Cellular Therapeutics To Advance Regulatory T Cell Exosome Platform Into Clinic

6/20/24 8:58:49 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $COYA alert in real time by email

Joint effort to leverage existing collaboration and non-dilutive grants to advance development of proprietary Treg exosome technology towards a first-in-human clinical study, continue work on validating biomarkers in a variety of neurodegenerative diseases, and explore novel synergistic drug combinations with COYA 301 (proprietary Low Dose Interleukin-2, or LD IL-2)

Get the next $COYA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$COYA

Date	Price Target	Rating	Analyst

More analyst ratings

$COYA
Press Releases

Fastest customizable press release news feed in the world

Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer
Company underscores potential benefits of low-dose interleukin-2 in Investigator-Initiated Phase 2 Alzheimer's disease trial as presented at the recent CTAD Conference Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that, as previously disclosed, Arun Swaminathan, Ph.D., has been promoted to Chief Executive Officer, effective today, November 1, 2024. Dr. Swaminathan was instrumental in executing several significant commercial transactions in his career, including Coya's licensing transaction with Dr. Reddy's Laboratory in December 2023 that could be
11/1/24 8:15:00 AM ET
$COYA
Biotechnology: Pharmaceutical Preparations
Health Care
Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer's Disease (AD) Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid (Spain)
Study met Primary and Secondary Endpoints for Safety and Regulatory T cell (Treg) Cell Population Enhancement, respectively, with no off-target effects on T effector lymphocytes, providing further evidence of target engagement Exploratory Endpoints demonstrated cognitive stabilization on treatment vs. cognitive declines on placebo for LD IL-2 dosing every 4 weeks (LD IL-2 q4wks), which was associated with significant improvement in cerebrospinal fluid (CSF) soluble Aβ42 levels and stabilized CSF Neurofilament Light Chain (NfL) Study supports and increases confidence in Treg modulation strategies in neurodegenerative conditions and in advancing LD IL-2 q4wks and LD IL-2 q4wks combinat
10/29/24 6:30:00 AM ET
$COYA
Biotechnology: Pharmaceutical Preparations
Health Care
Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer's Disease
Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces it will conduct a conference call on Tuesday, October 29, at 8am ET to discuss results from a placebo-controlled, investigator-initiated Phase 2 clinical trial of low-dose interleukin-2 (LD IL-2) in patients with mild to moderate Alzheimer's Disease (AD). These clinical results will be presented simultaneously via a poster on Tuesday, October 29, at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid, Spain. The Phase 2 study was led by KOLs Dr. Alireza Faridar and Dr. Stanley
10/28/24 8:00:00 AM ET
$COYA
Biotechnology: Pharmaceutical Preparations
Health Care

$COYA
Leadership Updates

Live Leadership Updates

Mr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc.
Secretary Ross has over 55 years' experience as a business leader, banker, and investor and is the former Chairman and Chief Strategy Officer of WL Ross & Co. Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced that it has appointed Secretary Wilbur Ross to its board of directors, effective immediately. Coya intends to leverage Secretary Ross's extensive experience in both the business and investment community to help guide strategic partnering activities, capital markets initiatives and drug development programs. S
12/20/23 8:30:00 AM ET
$COYA
Biotechnology: Pharmaceutical Preparations
Health Care
Coya Therapeutics' CEO Dr. Howard Berman's Letter to Stockholders
Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today released the following letter to stockholders from its Chief Executive Officer and Chairman, Dr. Howard Berman. Dear Fellow Stockholders, As the year comes to a close, I want to take a moment to reflect on Coya's accomplishments and share our strategic vision for the coming year. We set ambitious goals at the beginning of 2023 and I am pleased to say that our team rose to the occasion. Throughout the year, we notched several "wins," culminating in a transformative licensing transaction, announced December 6th, 2023, with Dr
12/13/23 8:00:00 AM ET
$COYA
Biotechnology: Pharmaceutical Preparations
Health Care
Coya Therapeutics Announces $26.5 Million Private Placement
Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of regulatory T cells ("Tregs"), announced today that it has entered into definitive securities purchase agreements for the purchase and sale of an aggregate of 4,370,382 shares of its common stock at a purchase price of $6.06 per share of common stock, in a private placement priced at-the-market under Nasdaq rules. The offering is expected to close on or about December 11, 2023, subject to the satisfaction of customary closing conditions. The financing included participation by former U.S. Secretary of Commerce Wi
12/6/23 7:05:00 AM ET
$COYA
Biotechnology: Pharmaceutical Preparations
Health Care

$COYA
Financials

Live finance-specific insights

Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer's Disease
Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces it will conduct a conference call on Tuesday, October 29, at 8am ET to discuss results from a placebo-controlled, investigator-initiated Phase 2 clinical trial of low-dose interleukin-2 (LD IL-2) in patients with mild to moderate Alzheimer's Disease (AD). These clinical results will be presented simultaneously via a poster on Tuesday, October 29, at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid, Spain. The Phase 2 study was led by KOLs Dr. Alireza Faridar and Dr. Stanley
10/28/24 8:00:00 AM ET
$COYA
Biotechnology: Pharmaceutical Preparations
Health Care
Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results
Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced its financial results for the third quarter ended September 30, 2023, and provided a clinical and business update. Q3 2023 and Recent Highlights Completed enrollment in a randomized, double-blind, placebo-controlled Phase 2 study of Low Dose IL-2 in patients with mild-to-moderate Alzheimer's Disease (AD). The study is being conducted by Drs. Stanley Appel and Alireza Faridar at the Houston Methodist Hospital and is funded by the Gates Foundation and Alzheimer's As
11/8/23 9:00:00 AM ET
$COYA
Biotechnology: Pharmaceutical Preparations
Health Care
Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results
Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced its financial results for the second quarter ended June 30, 2023, and provided a clinical and business update. Q2 2023 and Recent Highlights Presented positive results from a proof-of-concept (PoC), open-label, investigator-initiated clinical study of low dose interleukin-2 (ld IL-2) + CTLA4 Ig in Amyotrophic Lateral Sclerosis (ALS) illustrating enhancement of Treg function during the treatment period, halting of disease progression at 24 weeks and minimal decline a
8/8/23 7:00:00 AM ET
$COYA
Biotechnology: Pharmaceutical Preparations
Health Care

Coya Therapeutics Expands Sponsored Research Collaboration With Houston Methodist Research Institute With Funding From Johnson Center For Cellular Therapeutics To Advance Regulatory T Cell Exosome Platform Into Clinic

Chat with this insight

Recent Analyst Ratings for
$COYA

$COYA
SEC Filings

SEC Form 10-Q filed by Coya Therapeutics Inc.

Coya Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 8-K filed by Coya Therapeutics Inc.

$COYA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Coya Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Coya Therapeutics Inc.

$COYA
Press Releases

Fastest customizable press release news feed in the world

Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer

Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer's Disease (AD) Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid (Spain)

Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer's Disease

$COYA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 3 filed by new insider Swaminathan Arun

SEC Form 4 filed by Grossman Fred

SEC Form 4 filed by Snyder David S

$COYA
Leadership Updates

Live Leadership Updates

Mr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc.

Coya Therapeutics' CEO Dr. Howard Berman's Letter to Stockholders

Coya Therapeutics Announces $26.5 Million Private Placement

$COYA
Financials

Live finance-specific insights

Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer's Disease

Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results

Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results

$COYA
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Lee Ann bought $3,620 worth of shares (1,000 units at $3.62) (SEC Form 4)

$COYA
Market Insights

Live Market Insights

Coya Therapeutics Expands Sponsored Research Collaboration With Houston Methodist Research Institute With Funding From Johnson Center For Cellular Therapeutics To Advance Regulatory T Cell Exosome Platform Into Clinic

Rodman & Renshaw Initiates Coverage On Coya Therapeutics with Buy Rating, Announces Price Target of $18

Coya Therapeutics Expands Sponsored Research Collaboration With Houston Methodist Research Institute With Funding From Johnson Center For Cellular Therapeutics To Advance Regulatory T Cell Exosome Platform Into Clinic

Chat with this insight

Recent Analyst Ratings for $COYA

$COYA SEC Filings

SEC Form 10-Q filed by Coya Therapeutics Inc.

Coya Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 8-K filed by Coya Therapeutics Inc.

$COYA Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Coya Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Coya Therapeutics Inc.

$COYA Press Releases

Fastest customizable press release news feed in the world

Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer

Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer's Disease (AD) Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid (Spain)

Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer's Disease

$COYA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 3 filed by new insider Swaminathan Arun

SEC Form 4 filed by Grossman Fred

SEC Form 4 filed by Snyder David S

$COYA Leadership Updates

Live Leadership Updates

Mr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc.

Coya Therapeutics' CEO Dr. Howard Berman's Letter to Stockholders

Coya Therapeutics Announces $26.5 Million Private Placement

$COYA Financials

Live finance-specific insights

Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer's Disease

Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results

Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results

$COYA Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Lee Ann bought $3,620 worth of shares (1,000 units at $3.62) (SEC Form 4)

$COYA Market Insights

Live Market Insights

Coya Therapeutics Expands Sponsored Research Collaboration With Houston Methodist Research Institute With Funding From Johnson Center For Cellular Therapeutics To Advance Regulatory T Cell Exosome Platform Into Clinic

Rodman & Renshaw Initiates Coverage On Coya Therapeutics with Buy Rating, Announces Price Target of $18

Recent Analyst Ratings for
$COYA

$COYA
SEC Filings

$COYA
Large Ownership Changes

$COYA
Press Releases

$COYA
Insider Trading

$COYA
Leadership Updates

$COYA
Financials

$COYA
Insider Purchases

$COYA
Market Insights